Abbott pulls obesity drug from US market
After European tests found the key ingredient increased the risk of serious heart problems, Abbott Laboratories on Oct. 8 said it was pulling its obesity drug Meridia from the US market.
In a potentially groundbreaking study that could have significant implications in the fight against obesity, researchers in Texas have shown how an experimental drug, designed to destroy the blood supply to fat cells, has helped fat monkeys lose weight.